Category: Pharmaceutical Industry
-
Kerala HC widens patent ‘government-use’ power for cheap life-saving drugs, but leaves the trigger to the Center
After a breast-cancer patient’s death turned the plea into a suo motu cause, the Kerala High Court held that Section 100 of the Patents Act lets the government make and sell patented medicines cheaply, but left the decision to the Regional Cancer Center.
-
Janssen wins landmark preliminary injunction in District of Delaware
The U.S. District Court has issued a preliminary injunction against Accord BioPharma and Bio- Thera Solutions over the alleged infringement of 17 of Janssen’s patents related to golimumab, a key ingredient in its drugs used to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis.
-
Novo Nordisk signs GLP-1 licensing agreement with China’s Hengrui Pharma
Novo Nordisk and Hengrui Pharma’s agreement, subject to antitrust approval, will allow Novo to obtain exclusive rights to develop, manufacture, and commercialize HRS-1596 globally, excluding mainland China, Hong Kong, Macao, and Taiwan.
-
UPC Brussels limits interveners’ ability to pursue independent claims
The UPC’s Brussels LD has rejected the NIH’s bid to be treated as a co-claimant in 2seventy Bio’s infringement case, holding that interveners are limited to supporting the claims of the party they join and cannot pursue an independent litigation position.
-
Daiichi Sankyo loses six CNIPA administrative patent-linkage cases over mirogabalin formulation patents
Daiichi Sankyo has now lost six Chinese patent-linkage cases over generic mirogabalin after the CNIPA found two dosage strengths outside three formulation patents. The rulings show the growing importance of CNIPA’s administrative route for resolving patent disputes before generic launch.
-
Abbott wins another UPC PI against glucose sensor rival Sibio
The UPC’s Milan Local Division has granted Abbott a second UPC-wide preliminary injunction in its patent infringement case against Chinese rival Sibio, despite allowing the latter’s late-presented claim construction arguments to be admitted.
-
Accord slapped with injunction in Munich after invalidity losses in EPO, German Federal Patent Court
The Munich I Regional Court has found that Accord infringed TOWA’s dabigatran etexilate patent, issuing an injunction against the company. Dabigatran etexilate is an oral anticoagulant medicine that stops blood clots from forming, preventing strokes, deep vein thrombosis, and pulmonary embolism, among other things.
-
Lupin granted win against Vertex in Delaware over cystic fibrosis drug patents
Lupin’s generic version of Vertex’s cystic fibrosis treatment Kalydeco does not infringe the latter’s patents, Judge Stephanos Bibas of the Third Circuit has ruled.
-
FTC urges Fourth Circuit to reject Amgen plea to shield Roche patent acquisition: deal “threatens to upend” long-settled antitrust framework
The U.S. Federal Trade Commission has filed an amicus brief in an antitrust case between CareFirst and Amgen, urging the Fourth Circuit to reject Amgen’s bid to shield its acquisition of pending patent applications from antitrust scrutiny, as such procurements violate the Sherman Act and are not immunized by the Noerr-Pennington doctrine.
-
China’s top court overturns Nefecon generic PI despite U.S. Paragraph III-style no-launch pledge
A Chinese generic of Nefecon obtained formal approval after promising not to launch until patent expiry, then used that approval to seek procurement listings. China’s top court nevertheless held that the broken Paragraph III-style pledge was a regulatory breach – not an admission of patent infringement.